MY169330A - Method for inhibition of deubiquitinating activity - Google Patents
Method for inhibition of deubiquitinating activityInfo
- Publication number
- MY169330A MY169330A MYPI2014001125A MYPI2014001125A MY169330A MY 169330 A MY169330 A MY 169330A MY PI2014001125 A MYPI2014001125 A MY PI2014001125A MY PI2014001125 A MYPI2014001125 A MY PI2014001125A MY 169330 A MY169330 A MY 169330A
- Authority
- MY
- Malaysia
- Prior art keywords
- inhibition
- compound
- deubiquitinating activity
- treatment
- deubiquitinating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1100776 | 2011-10-19 | ||
| SE1200303 | 2012-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY169330A true MY169330A (en) | 2019-03-21 |
Family
ID=48141165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014001125A MY169330A (en) | 2011-10-19 | 2012-10-15 | Method for inhibition of deubiquitinating activity |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9221761B2 (enExample) |
| EP (1) | EP2780326B1 (enExample) |
| JP (1) | JP6165748B2 (enExample) |
| KR (1) | KR102022575B1 (enExample) |
| CN (1) | CN104271557B (enExample) |
| AU (1) | AU2012326682B2 (enExample) |
| BR (1) | BR112014009365B1 (enExample) |
| CA (1) | CA2852518C (enExample) |
| CL (1) | CL2014000998A1 (enExample) |
| DK (1) | DK2780326T3 (enExample) |
| EA (1) | EA026409B1 (enExample) |
| ES (1) | ES2713484T3 (enExample) |
| HU (1) | HUE041816T2 (enExample) |
| IL (1) | IL232118A (enExample) |
| MX (1) | MX345467B (enExample) |
| MY (1) | MY169330A (enExample) |
| PL (1) | PL2780326T3 (enExample) |
| PT (1) | PT2780326T (enExample) |
| SG (1) | SG11201401608PA (enExample) |
| WO (1) | WO2013058691A1 (enExample) |
| ZA (1) | ZA201403302B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE041816T2 (hu) * | 2011-10-19 | 2019-05-28 | Vivolux Ab | Módszer deubikitinációs aktivitás gátlására |
| EP2938610A2 (en) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| WO2016004221A1 (en) * | 2014-07-01 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| LT3277677T (lt) * | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| CN106146542A (zh) * | 2015-04-23 | 2016-11-23 | 北京大学 | 姜黄素硼酸衍生物,其制备方法和应用 |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| US10416163B2 (en) * | 2016-02-26 | 2019-09-17 | Regents Of The University Of Minnesota | Method and treatment of recurring endometrial cancer with an inhibitor of USP14 |
| SG11201907844TA (en) * | 2017-01-30 | 2019-09-27 | Up Therapeutics Inc | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CN111956804B (zh) * | 2020-07-21 | 2022-01-07 | 广州医科大学 | Otub1的抑制剂的新应用 |
| CN114959036A (zh) * | 2022-06-07 | 2022-08-30 | 北京大学 | Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU779230C (en) * | 1999-12-03 | 2006-05-25 | Emory University | Curcumin analogues for treating cancer |
| JP2005529080A (ja) * | 2002-03-08 | 2005-09-29 | エモリー ユニバーシティ | 腫瘍の増殖および脈管形成のサプレッサとしての新規のクルクミノイド−第ＶＩＩａ因子構築物 |
| WO2007007207A2 (en) * | 2005-04-13 | 2007-01-18 | Khairia Youssef | Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation |
| EP1749822B1 (en) * | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
| JP2009516656A (ja) * | 2005-11-22 | 2009-04-23 | ユニバーシティ オブ サスカチュワン | 抗腫瘍活性化合物 |
| US20120316203A1 (en) * | 2009-07-06 | 2012-12-13 | The Ohio State University Research Foundation | Compositions and Methods for Inhibition of Cancers |
| HUE041816T2 (hu) * | 2011-10-19 | 2019-05-28 | Vivolux Ab | Módszer deubikitinációs aktivitás gátlására |
-
2012
- 2012-10-15 HU HUE12841677A patent/HUE041816T2/hu unknown
- 2012-10-15 PT PT12841677T patent/PT2780326T/pt unknown
- 2012-10-15 CN CN201280062713.XA patent/CN104271557B/zh not_active Expired - Fee Related
- 2012-10-15 EA EA201490800A patent/EA026409B1/ru not_active IP Right Cessation
- 2012-10-15 CA CA2852518A patent/CA2852518C/en active Active
- 2012-10-15 MX MX2014004646A patent/MX345467B/es active IP Right Grant
- 2012-10-15 AU AU2012326682A patent/AU2012326682B2/en not_active Ceased
- 2012-10-15 KR KR1020147012947A patent/KR102022575B1/ko not_active Expired - Fee Related
- 2012-10-15 JP JP2014537023A patent/JP6165748B2/ja not_active Expired - Fee Related
- 2012-10-15 MY MYPI2014001125A patent/MY169330A/en unknown
- 2012-10-15 PL PL12841677T patent/PL2780326T3/pl unknown
- 2012-10-15 DK DK12841677.3T patent/DK2780326T3/en active
- 2012-10-15 EP EP12841677.3A patent/EP2780326B1/en active Active
- 2012-10-15 SG SG11201401608PA patent/SG11201401608PA/en unknown
- 2012-10-15 BR BR112014009365-2A patent/BR112014009365B1/pt not_active IP Right Cessation
- 2012-10-15 ES ES12841677T patent/ES2713484T3/es active Active
- 2012-10-15 WO PCT/SE2012/000158 patent/WO2013058691A1/en not_active Ceased
-
2014
- 2014-04-13 IL IL232118A patent/IL232118A/en active IP Right Grant
- 2014-04-17 CL CL2014000998A patent/CL2014000998A1/es unknown
- 2014-04-18 US US14/256,280 patent/US9221761B2/en not_active Expired - Fee Related
- 2014-05-08 ZA ZA2014/03302A patent/ZA201403302B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX345467B (es) | Metodo para inhibicion de actividad desubiquitinante. | |
| NZ709635A (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
| UA111386C2 (uk) | Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ | |
| MX382562B (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub). | |
| MX336214B (es) | Derivados de pirrolotriazinona como inhibidores de pi3k. | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| MY183661A (en) | Treatment of cancer with tor kinase inhibitors | |
| PH12014501542A1 (en) | Substituted pyrrolidine -2- carboxamides | |
| MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| MX2013012979A (es) | Piridina y derivados de pirazina. | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| PH12014501639A1 (en) | Pharmaceutical compositions and methods | |
| PH12015501088A1 (en) | Dimeric compounds | |
| GEP20115342B (en) | New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | |
| MX350112B (es) | Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk. | |
| MX2011011083A (es) | Compuestos heterociclicos como inhibidores de mek. | |
| MX2013012977A (es) | Derivados de tiazol. | |
| PH12014500990A1 (en) | Methods for treating gout flares | |
| MX2014000150A (es) | Sistemas, metodos y formulaciones para tratamiento de cancer. | |
| MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
| MX366140B (es) | Derivados de urea de piperidinas. |